Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Assets (2020 - 2023)

Candel Therapeutics' Non-Current Assets history spans 4 years, with the latest figure at $5.0 million for Q3 2023.

  • For Q3 2023, Non-Current Assets fell 16.46% year-over-year to $5.0 million; the TTM value through Sep 2023 reached $21.4 million, down 3.05%, while the annual FY2022 figure was $5.7 million, 34.88% up from the prior year.
  • Non-Current Assets for Q3 2023 was $5.0 million at Candel Therapeutics, down from $5.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.3 million in Q2 2021 and bottomed at $3.1 million in Q4 2020.
  • The 4-year median for Non-Current Assets is $5.4 million (2023), against an average of $5.3 million.
  • The largest annual shift saw Non-Current Assets surged 35.84% in 2021 before it dropped 16.46% in 2023.
  • A 4-year view of Non-Current Assets shows it stood at $3.1 million in 2020, then soared by 35.84% to $4.3 million in 2021, then surged by 34.88% to $5.7 million in 2022, then decreased by 13.68% to $5.0 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Non-Current Assets are $5.0 million (Q3 2023), $5.3 million (Q2 2023), and $5.4 million (Q1 2023).